Shingles Vaccine Market Size, Share, Growth Analysis, By Product (Shingrix, Zostavax), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By Region - Industry Forecast 2025-2032

Capturing a substantial share of over 80.0% in 2022, North America emerged as the dominant player. This market ascendancy is underpinned by several factors, including the strategic presence of key industry players, advantageous reimbursement policies, and a commendable vaccine adoption rate. Notably, the U.S. exhibits a vaccine uptake of approximately 35%, while Canada registers more than 20% of its eligible population benefiting from the vaccine. The region's elevated awareness levels and robust recommendation for shingles vaccination contribute significantly to its growth trajectory throughout the forecast period. Both the U.S. and Canada prioritize Shingrix as the preferred option over Zostavax for shingles prevention due to the demonstrated high efficacy of Shingrix.

Meanwhile, the Asia Pacific region is poised to manifest the most rapid growth rate during the forecast period. This growth is attributed to escalating disposable incomes, healthcare policy enhancements, and a substantial population segment at high risk of shingles. Moreover, the region's lower- and middle-income countries, characterized by unmet medical needs, are expected to stimulate market expansion. The endorsement of Shingrix across several Asian nations further accelerates the region's market growth. These dynamics collectively position North America as the present leader while paving the way for the Asia Pacific to emerge as a burgeoning market force.